To examine factors to predict the optimal stent pusher position when inserting ureteral stents under fluoroscopy.
Methods
We retrospectively reviewed 327 patients who underwent ureteral stent insertion. We considered the pubic bone as a useful anatomical landmark to insert ureteral stents under fluoroscopic guidance. Thus, we categorized patients into three groups (proximal, middle, and distal groups) according to the position of the radiopaque tip of the push catheter when inserting the ureteral stent. Success was defined as a completely curled ureteral stent tail. We compared stent insertion success rates among the three groups. A multivariate analysis was performed to identify the factors affecting stent insertion success.
Results
In men, 36 (63.2%) cases were deemed successful in the proximal group compared with 40 (80.0%) cases in the middle group and 12 (20.7%) cases in the distal group (p<0.001). In women, 26 (45.6%) cases were deemed successful in the proximal group compared with 54 (98.2%) cases in the middle group and 38 (76.0%) cases in the distal group (p<0.001). With the multivariate analysis, the stent pusher position was the most significant factor influencing successful stent insertion (men: odds ratio 6.00, 95% confidence interval 2.66–13.51, p<0.001; women: odds ratio 37.80, 95% confidence interval 4.94–289.22, p<0.001).
Conclusion
The position of the stent pusher affects stent insertion success. The middle of the pubic symphysis is the optimal position for the radiopaque tip of the pusher when inserting ureteral stents under fluoroscopic guidance.
{"title":"The optimal stent pusher position to achieve successful ureteral stent insertion under fluoroscopic guidance","authors":"Makoto Taguchi , Kaneki Yasuda , Hidefumi Kinoshita","doi":"10.1016/j.ajur.2022.11.006","DOIUrl":"10.1016/j.ajur.2022.11.006","url":null,"abstract":"<div><h3>Objective</h3><p>To examine factors to predict the optimal stent pusher position when inserting ureteral stents under fluoroscopy.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed 327 patients who underwent ureteral stent insertion. We considered the pubic bone as a useful anatomical landmark to insert ureteral stents under fluoroscopic guidance. Thus, we categorized patients into three groups (proximal, middle, and distal groups) according to the position of the radiopaque tip of the push catheter when inserting the ureteral stent. Success was defined as a completely curled ureteral stent tail. We compared stent insertion success rates among the three groups. A multivariate analysis was performed to identify the factors affecting stent insertion success.</p></div><div><h3>Results</h3><p>In men, 36 (63.2%) cases were deemed successful in the proximal group compared with 40 (80.0%) cases in the middle group and 12 (20.7%) cases in the distal group (<em>p</em><0.001). In women, 26 (45.6%) cases were deemed successful in the proximal group compared with 54 (98.2%) cases in the middle group and 38 (76.0%) cases in the distal group (<em>p</em><0.001). With the multivariate analysis, the stent pusher position was the most significant factor influencing successful stent insertion (men: odds ratio 6.00, 95% confidence interval 2.66–13.51, <em>p</em><0.001; women: odds ratio 37.80, 95% confidence interval 4.94–289.22, <em>p</em><0.001).</p></div><div><h3>Conclusion</h3><p>The position of the stent pusher affects stent insertion success. The middle of the pubic symphysis is the optimal position for the radiopaque tip of the pusher when inserting ureteral stents under fluoroscopic guidance.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 311-315"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223001261/pdfft?md5=4d7bf23150086ac9b4e52826040d0b23&pid=1-s2.0-S2214388223001261-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135763477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2024.01.008
Palle J.S. Osther, Susanne S. Osther, Maria P. Hesselholt, Sofia Byllov, Søren K. Lildal, Louise F. Øbro, Helene Jung
{"title":"Understanding intrarenal backflow: Intrarenal pressure during ureteroscopy and beyond","authors":"Palle J.S. Osther, Susanne S. Osther, Maria P. Hesselholt, Sofia Byllov, Søren K. Lildal, Louise F. Øbro, Helene Jung","doi":"10.1016/j.ajur.2024.01.008","DOIUrl":"10.1016/j.ajur.2024.01.008","url":null,"abstract":"","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 139-142"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388224000080/pdfft?md5=d34abf3711e9895e610dc726bfb3d595&pid=1-s2.0-S2214388224000080-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139883865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2022.08.007
Ryan A. Dornbier , Chirag P. Doshi , Shalin C. Desai , Petar Bajic , Michelle Van Kuiken , Mark Khemmani , Ahmer V. Farooq , Larissa Bresler , Thomas M.T. Turk , Alan J. Wolfe , Kristin G. Baldea
Objective
To identify possible stone-promoting microbes, we compared the profiles of microbes grown from stones of patients with and without metabolic syndrome (MetS). The association between MetS and urinary stone disease is well established, but the exact pathophysiologic relationship remains unknown. Recent evidence suggests urinary tract dysbiosis may lead to increased nephrolithiasis risk.
Methods
At the time of percutaneous nephrolithotomy, bladder urine and stone fragments were collected from patients with and without MetS. Both sample types were subjected to expanded quantitative urine culture (EQUC) and 16 S ribosomal RNA gene sequencing.
Results
Fifty-seven patients included 12 controls (21.1%) and 45 MetS patients (78.9%). Both cohorts were similar with respect to demographics and non-MetS comorbidities. No controls had uric acid stone composition. By EQUC, bacteria were detected more frequently in MetS stones (42.2%) compared to controls (8.3%) (p=0.041). Bacteria also were more abundant in stones of MetS patients compared to controls. To validate our EQUC results, we performed 16 S ribosomal RNA gene sequencing. In 12/16 (75.0%) sequence-positive stones, EQUC reliably isolated at least one species of the sequenced genera. Bacteria were detected in both “infectious” and “non-infectious” stone compositions.
Conclusion
Bacteria are more common and more abundant in MetS stones than control stones. Our findings support a role for bacteria in urinary stone disease for patients with MetS regardless of stone composition.
{"title":"Metabolic syndrome and the urinary microbiome of patients undergoing percutaneous nephrolithotomy","authors":"Ryan A. Dornbier , Chirag P. Doshi , Shalin C. Desai , Petar Bajic , Michelle Van Kuiken , Mark Khemmani , Ahmer V. Farooq , Larissa Bresler , Thomas M.T. Turk , Alan J. Wolfe , Kristin G. Baldea","doi":"10.1016/j.ajur.2022.08.007","DOIUrl":"10.1016/j.ajur.2022.08.007","url":null,"abstract":"<div><h3>Objective</h3><p>To identify possible stone-promoting microbes, we compared the profiles of microbes grown from stones of patients with and without metabolic syndrome (MetS). The association between MetS and urinary stone disease is well established, but the exact pathophysiologic relationship remains unknown. Recent evidence suggests urinary tract dysbiosis may lead to increased nephrolithiasis risk.</p></div><div><h3>Methods</h3><p>At the time of percutaneous nephrolithotomy, bladder urine and stone fragments were collected from patients with and without MetS. Both sample types were subjected to expanded quantitative urine culture (EQUC) and 16 S ribosomal RNA gene sequencing.</p></div><div><h3>Results</h3><p>Fifty-seven patients included 12 controls (21.1%) and 45 MetS patients (78.9%). Both cohorts were similar with respect to demographics and non-MetS comorbidities. No controls had uric acid stone composition. By EQUC, bacteria were detected more frequently in MetS stones (42.2%) compared to controls (8.3%) (<em>p</em>=0.041). Bacteria also were more abundant in stones of MetS patients compared to controls. To validate our EQUC results, we performed 16 S ribosomal RNA gene sequencing. In 12/16 (75.0%) sequence-positive stones, EQUC reliably isolated at least one species of the sequenced genera. Bacteria were detected in both “infectious” and “non-infectious” stone compositions.</p></div><div><h3>Conclusion</h3><p>Bacteria are more common and more abundant in MetS stones than control stones. Our findings support a role for bacteria in urinary stone disease for patients with MetS regardless of stone composition.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 316-323"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000292/pdfft?md5=7ff3f9efd25e80fed3e36afad0333c83&pid=1-s2.0-S2214388223000292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42343026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2023.03.004
Kyo Chul Koo , Abdulghafour Halawani , Victor K.F. Wong , Dirk Lange , Ben H. Chew
Objective
Urolithiasis formation has been attributed to environmental and dietary factors. However, evidence is accumulating that genetic background can contribute to urolithiasis formation. Advancements in the identification of monogenic causes using high-throughput sequencing technologies have shown that urolithiasis has a strong heritable component.
Methods
This review describes monogenic factors implicated in a genetic predisposition to urolithiasis. Peer-reviewed journals were evaluated by a PubMed search until July 2023 to summarize disorders associated with monogenic traits, and discuss clinical implications of identification of patients genetically susceptible to urolithiasis formation.
Results
Given that more than 80% of urolithiases cases are associated with calcium accumulation, studies have focused mainly on monogenetic contributors to hypercalciuric urolithiases, leading to the identification of receptors, channels, and transporters involved in the regulation of calcium renal tubular reabsorption. Nevertheless, available candidate genes and linkage methods have a low resolution for evaluation of the effects of genetic components versus those of environmental, dietary, and hormonal factors, and genotypes remain undetermined in the majority of urolithiasis formers.
Conclusion
The pathophysiology underlying urolithiasis formation is complex and multifactorial, but evidence strongly suggests the existence of numerous monogenic causes of urolithiasis in humans.
{"title":"Monogenic features of urolithiasis: A comprehensive review","authors":"Kyo Chul Koo , Abdulghafour Halawani , Victor K.F. Wong , Dirk Lange , Ben H. Chew","doi":"10.1016/j.ajur.2023.03.004","DOIUrl":"10.1016/j.ajur.2023.03.004","url":null,"abstract":"<div><h3>Objective</h3><p>Urolithiasis formation has been attributed to environmental and dietary factors. However, evidence is accumulating that genetic background can contribute to urolithiasis formation. Advancements in the identification of monogenic causes using high-throughput sequencing technologies have shown that urolithiasis has a strong heritable component.</p></div><div><h3>Methods</h3><p>This review describes monogenic factors implicated in a genetic predisposition to urolithiasis. Peer-reviewed journals were evaluated by a PubMed search until July 2023 to summarize disorders associated with monogenic traits, and discuss clinical implications of identification of patients genetically susceptible to urolithiasis formation.</p></div><div><h3>Results</h3><p>Given that more than 80% of urolithiases cases are associated with calcium accumulation, studies have focused mainly on monogenetic contributors to hypercalciuric urolithiases, leading to the identification of receptors, channels, and transporters involved in the regulation of calcium renal tubular reabsorption. Nevertheless, available candidate genes and linkage methods have a low resolution for evaluation of the effects of genetic components versus those of environmental, dietary, and hormonal factors, and genotypes remain undetermined in the majority of urolithiasis formers.</p></div><div><h3>Conclusion</h3><p>The pathophysiology underlying urolithiasis formation is complex and multifactorial, but evidence strongly suggests the existence of numerous monogenic causes of urolithiasis in humans.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 169-179"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000401/pdfft?md5=d401195c994e56bfe704e3fac47918aa&pid=1-s2.0-S2214388223000401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43231155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2022.09.002
Ahmed M. Harraz, Ahmed Elkarta, Mohamed H. Zahran, Ahmed Mosbah, Atallah A. Shaaban, Hassan Abol-Enein
Objective
To develop and internally validate a nomogram to predict recurrence-free survival (RFS) including the time to radical cystectomy (RC) and perioperative blood transfusion (PBT) as potential predictors.
Methods
Patients who underwent open RC and ileal conduit between January 1996 to December 2016 were split into developing (n=948) and validating (n=237) cohorts. The time to radical cystectomy (TTC) was defined as the interval between the onset of symptoms and RC. The regression coefficients of the independent predictors obtained by Cox regression were used to construct the nomogram. Discrimination, validation, and clinical usefulness in the validation cohort were assessed by the area under the curve, the calibration plot, and decision curve analysis.
Results
In the developing dataset, the 1-, 5-, and 10-year RFS were 83.0%, 47.2%, and 44.4%, respectively. On multivariate analysis, independent predictors were TTC (hazards ratio [HR] 1.07, 95% confidence interval [CI] 1.05–1.08, p<0.001), PBT (one unit: HR 1.40, 95% CI 1.03–1.90, p=0.03; two or more units: HR 1.72, 95% CI 1.29–2.29, p<0.001), bilateral hydronephrosis (HR 1.54, 95% CI 1.21–1.97, p<0.001), squamous cell carcinoma (HR 0.60, 95% CI 0.45–0.81, p=0.001), pT3-T4 (HR 1.77, 95% CI 1.41–2.22, p<0.001), lymph node status (HR 1.53, 95% CI 1.21–1.95, p<0.001), and lymphovascular invasion (HR 1.28, 95% CI 1.01–1.62, p=0.044). The areas under the curve in the validation dataset were 79.3%, 69.6%, and 76.2%, for 1-, 5-, and 10-year RFS, respectively. Calibration plots showed considerable correspondence between predicted and actual survival probabilities. The decision curve analysis revealed a better net benefit of the nomogram.
Conclusion
A nomogram with good discrimination, validation, and clinical utility was constructed utilizing TTC and PBT in addition to standard pathological criteria.
方法将 1996 年 1 月至 2016 年 12 月间接受开放性膀胱切除术(RC)和回肠导管手术的患者分为开发组(948 人)和验证组(237 人)。根治性膀胱切除术(TTC)的时间定义为症状出现与 RC 之间的时间间隔。通过 Cox 回归获得的独立预测因子的回归系数用于构建提名图。通过曲线下面积、校准图和决策曲线分析评估了验证队列中的鉴别、验证和临床实用性。多变量分析显示,独立预测因子为 TTC(危险比 [HR] 1.07,95% 置信区间 [CI] 1.05-1.08,p<0.001)、PBT(一个单位:HR 1.40,95% CI 1.03-1.90,p=0.03;两个或两个以上单位:HR 1.72,95% CI 1.29-2.29,p<0.001)、双侧肾积水(HR 1.54,95% CI 1.21-1.97,p<0.001)、鳞状细胞癌(HR 0.60,95% CI 0.45-0.81,p=0.001)、pT3-T4(HR 1.77,95% CI 1.41-2.22,p<0.001)、淋巴结状态(HR 1.53,95% CI 1.21-1.95,p<0.001)和淋巴管侵犯(HR 1.28,95% CI 1.01-1.62,p=0.044)。在验证数据集中,1 年、5 年和 10 年 RFS 的曲线下面积分别为 79.3%、69.6% 和 76.2%。校准图显示,预测生存概率与实际生存概率之间存在相当大的对应关系。结论 除了标准病理标准外,还利用 TTC 和 PBT 构建了一个具有良好区分度、验证和临床实用性的提名图。
{"title":"The impact of chemotherapy-naïve open radical cystectomy delay and perioperative transfusion on the recurrence-free survival: A perioperative parameters-based nomogram","authors":"Ahmed M. Harraz, Ahmed Elkarta, Mohamed H. Zahran, Ahmed Mosbah, Atallah A. Shaaban, Hassan Abol-Enein","doi":"10.1016/j.ajur.2022.09.002","DOIUrl":"10.1016/j.ajur.2022.09.002","url":null,"abstract":"<div><h3>Objective</h3><p>To develop and internally validate a nomogram to predict recurrence-free survival (RFS) including the time to radical cystectomy (RC) and perioperative blood transfusion (PBT) as potential predictors.</p></div><div><h3>Methods</h3><p>Patients who underwent open RC and ileal conduit between January 1996 to December 2016 were split into developing (<em>n</em>=948) and validating (<em>n</em>=237) cohorts. The time to radical cystectomy (TTC) was defined as the interval between the onset of symptoms and RC. The regression coefficients of the independent predictors obtained by Cox regression were used to construct the nomogram. Discrimination, validation, and clinical usefulness in the validation cohort were assessed by the area under the curve, the calibration plot, and decision curve analysis.</p></div><div><h3>Results</h3><p>In the developing dataset, the 1-, 5-, and 10-year RFS were 83.0%, 47.2%, and 44.4%, respectively. On multivariate analysis, independent predictors were TTC (hazards ratio [HR] 1.07, 95% confidence interval [CI] 1.05–1.08, <em>p</em><0.001), PBT (one unit: HR 1.40, 95% CI 1.03–1.90, <em>p</em>=0.03; two or more units: HR 1.72, 95% CI 1.29–2.29, <em>p</em><0.001), bilateral hydronephrosis (HR 1.54, 95% CI 1.21–1.97, <em>p</em><0.001), squamous cell carcinoma (HR 0.60, 95% CI 0.45–0.81, <em>p</em>=0.001), pT3-T4 (HR 1.77, 95% CI 1.41–2.22, <em>p</em><0.001), lymph node status (HR 1.53, 95% CI 1.21–1.95, <em>p</em><0.001), and lymphovascular invasion (HR 1.28, 95% CI 1.01–1.62, <em>p</em>=0.044). The areas under the curve in the validation dataset were 79.3%, 69.6%, and 76.2%, for 1-, 5-, and 10-year RFS, respectively. Calibration plots showed considerable correspondence between predicted and actual survival probabilities. The decision curve analysis revealed a better net benefit of the nomogram.</p></div><div><h3>Conclusion</h3><p>A nomogram with good discrimination, validation, and clinical utility was constructed utilizing TTC and PBT in addition to standard pathological criteria.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 294-303"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388222001321/pdfft?md5=462c9f1decf5dac275c950804f3342c2&pid=1-s2.0-S2214388222001321-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43511445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2022.11.005
Herney Andrés García-Perdomo , Angélica María Dávila-Raigoza , Fernando Korkes
Objective
Metabolomics has been extensively utilized in bladder cancer (BCa) research, employing mass spectrometry and nuclear magnetic resonance spectroscopy to compare various variables (tissues, serum, blood, and urine). This study aimed to identify potential biomarkers for early BCa diagnosis.
Methods
A search strategy was designed to identify clinical trials, descriptive and analytical observational studies from databases such as Medline, Embase, Cochrane Central Register of Controlled Trials, and Latin American and Caribbean Literature in Health Sciences. Inclusion criteria comprised studies involving BCa tissue, serum, blood, or urine profiling using widely adopted metabolomics techniques like mass spectrometry and nuclear magnetic resonance. Primary outcomes included description of metabolites and metabolomics profiling in BCa patients and the association of metabolites and metabolomics profiling with BCa diagnosis compared to control patients. The risk of bias was assessed using the Quality Assessment of Studies of Diagnostic Accuracy.
Results
The search strategy yielded 2832 studies, of which 30 case-control studies were included. Urine was predominantly used as the primary sample for metabolite identification. Risk of bias was often unclear inpatient selection, blinding of the index test, and reference standard assessment, but no applicability concerns were observed. Metabolites and metabolomics profiles associated with BCa diagnosis were identified in glucose, amino acids, nucleotides, lipids, and aldehydes metabolism.
Conclusion
The identified metabolites in urine included citric acid, valine, tryptophan, taurine, aspartic acid, uridine, ribose, phosphocholine, and carnitine. Tissue samples exhibited elevated levels of lactic acid, amino acids, and lipids. Consistent findings across tissue, urine, and serum samples revealed downregulation of citric acid and upregulation of lactic acid, valine, tryptophan, taurine, glutamine, aspartic acid, uridine, ribose, and phosphocholine.
目的代谢组学已广泛应用于膀胱癌(BCa)研究,利用质谱和核磁共振波谱比较各种变量(组织、血清、血液和尿液)。本研究旨在确定膀胱癌早期诊断的潜在生物标志物。方法设计了一种检索策略,从 Medline、Embase、Cochrane Central Register of Controlled Trials 以及拉丁美洲和加勒比海健康科学文献等数据库中确定临床试验、描述性和分析性观察研究。纳入标准包括使用广泛采用的代谢组学技术(如质谱法和核磁共振)对 BCa 组织、血清、血液或尿液进行分析的研究。主要结果包括对 BCa 患者代谢物和代谢组学分析的描述,以及与对照组患者相比,代谢物和代谢组学分析与 BCa 诊断的关联。采用诊断准确性研究质量评估方法对偏倚风险进行了评估。结果搜索策略共获得2832项研究,其中包括30项病例对照研究。尿液是鉴定代谢物的主要样本。存在偏倚风险的原因通常是住院病人选择不明确、指标检测存在盲法和参考标准评估,但未发现适用性问题。结论尿液中鉴定出的代谢物包括柠檬酸、缬氨酸、色氨酸、牛磺酸、天冬氨酸、尿苷、核糖、磷脂酰胆碱和肉碱。组织样本中的乳酸、氨基酸和脂质含量升高。组织、尿液和血清样本的一致发现表明,柠檬酸下调,乳酸、缬氨酸、色氨酸、牛磺酸、谷氨酰胺、天冬氨酸、尿苷、核糖和磷脂酰胆碱上调。
{"title":"Metabolomics for the diagnosis of bladder cancer: A systematic review","authors":"Herney Andrés García-Perdomo , Angélica María Dávila-Raigoza , Fernando Korkes","doi":"10.1016/j.ajur.2022.11.005","DOIUrl":"10.1016/j.ajur.2022.11.005","url":null,"abstract":"<div><h3>Objective</h3><p>Metabolomics has been extensively utilized in bladder cancer (BCa) research, employing mass spectrometry and nuclear magnetic resonance spectroscopy to compare various variables (tissues, serum, blood, and urine). This study aimed to identify potential biomarkers for early BCa diagnosis.</p></div><div><h3>Methods</h3><p>A search strategy was designed to identify clinical trials, descriptive and analytical observational studies from databases such as Medline, Embase, Cochrane Central Register of Controlled Trials, and Latin American and Caribbean Literature in Health Sciences. Inclusion criteria comprised studies involving BCa tissue, serum, blood, or urine profiling using widely adopted metabolomics techniques like mass spectrometry and nuclear magnetic resonance. Primary outcomes included description of metabolites and metabolomics profiling in BCa patients and the association of metabolites and metabolomics profiling with BCa diagnosis compared to control patients. The risk of bias was assessed using the Quality Assessment of Studies of Diagnostic Accuracy.</p></div><div><h3>Results</h3><p>The search strategy yielded 2832 studies, of which 30 case-control studies were included. Urine was predominantly used as the primary sample for metabolite identification. Risk of bias was often unclear inpatient selection, blinding of the index test, and reference standard assessment, but no applicability concerns were observed. Metabolites and metabolomics profiles associated with BCa diagnosis were identified in glucose, amino acids, nucleotides, lipids, and aldehydes metabolism.</p></div><div><h3>Conclusion</h3><p>The identified metabolites in urine included citric acid, valine, tryptophan, taurine, aspartic acid, uridine, ribose, phosphocholine, and carnitine. Tissue samples exhibited elevated levels of lactic acid, amino acids, and lipids. Consistent findings across tissue, urine, and serum samples revealed downregulation of citric acid and upregulation of lactic acid, valine, tryptophan, taurine, glutamine, aspartic acid, uridine, ribose, and phosphocholine.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 221-241"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000942/pdfft?md5=1d958191f1253c033ab7fc877456c4c2&pid=1-s2.0-S2214388223000942-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2023.07.001
Andrea Cocci , Marta Pezzoli , Fernando Bianco , Franco Blefari , Pierluigi Bove , Francois Cornud , Gaetano De Rienzo , Paolo Destefanis , Danilo Di Trapani , Alessandro Giacobbe , Luca Giovanessi , Antonino Laganà , Giovanni Lughezzani , Guglielmo Manenti , Gianluca Muto , Gianluigi Patelli , Novello Pinzi , Stefano Regusci , Giorgio I. Russo , Juan I.M. Salamanca , Francesco Sessa
Objective
To evaluate transperineal laser ablation (TPLA) with Echolaser® (Echolaser® TPLA, Elesta S.p.A., Calenzano, Italy) as a treatment for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) using the Delphi consensus method.
Methods
Italian and international experts on BPH and PCa participated in a collaborative consensus project. During two rounds, they expressed their opinions on Echolaser® TPLA for the treatment of BPH and PCa answering online questionnaires on indications, methodology, and potential complications of this technology. Level of agreement or disagreement to reach consensus was set at 75%. If the consensus was not achieved, questions were modified after each round. A final round was performed during an online meeting, in which results were discussed and finalized.
Results
Thirty-two out of forty invited experts participated and consensus was reached on all topics. Agreement was achieved on recommending Echolaser® TPLA as a treatment of BPH in patients with ample range of prostate volume, from <40 mL (80%) to >80 mL (80%), comorbidities (100%), antiplatelet or anticoagulant treatment (96%), indwelling catheter (77%), and strong will of preserving ejaculatory function (100%). Majority of respondents agreed that Echolaser® TPLA is a potential option for the treatment of localized PCa (78%) and recommended it for low-risk PCa (90%). During the final round, experts concluded that it can be used for intermediate-risk PCa and it should be proposed as an effective alternative to radical prostatectomy for patients with strong will of avoiding urinary incontinence and sexual dysfunction. Almost all participants agreed that the transperineal approach of this organ-sparing technique is safer than transrectal and transurethral approaches typical of other techniques (97% of agreement among experts). Pre-procedural assessment, technical aspects, post-procedural catheterization, pharmacological therapy, and expected outcomes were discussed, leading to statements and recommendations.
Conclusion
Echolaser® TPLA is a safe and effective procedure that treats BPH and localized PCa with satisfactory functional and sexual outcomes.
{"title":"Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project","authors":"Andrea Cocci , Marta Pezzoli , Fernando Bianco , Franco Blefari , Pierluigi Bove , Francois Cornud , Gaetano De Rienzo , Paolo Destefanis , Danilo Di Trapani , Alessandro Giacobbe , Luca Giovanessi , Antonino Laganà , Giovanni Lughezzani , Guglielmo Manenti , Gianluca Muto , Gianluigi Patelli , Novello Pinzi , Stefano Regusci , Giorgio I. Russo , Juan I.M. Salamanca , Francesco Sessa","doi":"10.1016/j.ajur.2023.07.001","DOIUrl":"10.1016/j.ajur.2023.07.001","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate transperineal laser ablation (TPLA) with Echolaser® (Echolaser® TPLA, Elesta S.p.A., Calenzano, Italy) as a treatment for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) using the Delphi consensus method.</p></div><div><h3>Methods</h3><p>Italian and international experts on BPH and PCa participated in a collaborative consensus project. During two rounds, they expressed their opinions on Echolaser® TPLA for the treatment of BPH and PCa answering online questionnaires on indications, methodology, and potential complications of this technology. Level of agreement or disagreement to reach consensus was set at 75%. If the consensus was not achieved, questions were modified after each round. A final round was performed during an online meeting, in which results were discussed and finalized.</p></div><div><h3>Results</h3><p>Thirty-two out of forty invited experts participated and consensus was reached on all topics. Agreement was achieved on recommending Echolaser® TPLA as a treatment of BPH in patients with ample range of prostate volume, from <40 mL (80%) to >80 mL (80%), comorbidities (100%), antiplatelet or anticoagulant treatment (96%), indwelling catheter (77%), and strong will of preserving ejaculatory function (100%). Majority of respondents agreed that Echolaser® TPLA is a potential option for the treatment of localized PCa (78%) and recommended it for low-risk PCa (90%). During the final round, experts concluded that it can be used for intermediate-risk PCa and it should be proposed as an effective alternative to radical prostatectomy for patients with strong will of avoiding urinary incontinence and sexual dysfunction. Almost all participants agreed that the transperineal approach of this organ-sparing technique is safer than transrectal and transurethral approaches typical of other techniques (97% of agreement among experts). Pre-procedural assessment, technical aspects, post-procedural catheterization, pharmacological therapy, and expected outcomes were discussed, leading to statements and recommendations.</p></div><div><h3>Conclusion</h3><p>Echolaser® TPLA is a safe and effective procedure that treats BPH and localized PCa with satisfactory functional and sexual outcomes.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 271-279"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000681/pdfft?md5=7a82d62e6c105c3e9b1a6609432714a7&pid=1-s2.0-S2214388223000681-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42598755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to explore the global, prevalence, and risk factors of fever after percutaneous nephrolithotomy (PCNL) by conducting a systematic review and meta-analysis.
Methods
The high-sensitivity searching was conducted without time limitation until December 30, 2020 in Web of Sciences, Scopus, and PubMed based on inclusion and exclusion criteria.
Results
The prevalence rates of fever and sepsis among patient undergoing PCNL were estimated 9.5% (95% confidence interval [CI]: 9.3%–9.7%), and 4.5% (95% CI: 4.2%–4.8%), respectively. Nephrostomy tube was used in 9.96% (95% CI: 9.94%–9.97%) of patients. The mean preoperative white blood cells of patients were 6.401×109/L; 18.3% and 4.55% of patients were considered as the positive urinary culture and pyuria, respectively. About 20.4% of patients suffered from residual stones. The odds ratios (ORs) of fever in patients who suffering from diabetes mellitus, hydronephrosis, staghorn stones, and blood transfusion were 4.62 (95% CI: 2.95–7.26), 1.04 (95% CI: 0.81–1.34), 2.57 (95% CI: 0.93–7.11), and 2.65 (95% CI: 1.62–4.35), respectively. Patients who underwent PCNL in prone position were more likely to develop fever (OR: 1.23; 95% CI: 0.75–2.00) than patients in supine position.
Conclusion
The current study showed that patients who suffer from diabetes mellitus, hydronephrosis, staghorn stones, nephrostomy tube or double-J stent, blood transfusion, and also patients who underwent PCNL in prone position surgery are more likely to develop a postoperative fever after PCNL.
{"title":"The global, prevalence, and risk factors of postoperative fever after percutaneous nephrolithotomy: A systematic review and meta-analysis","authors":"Reza Falahatkar , Siavash Falahatkar , Mohammad Amin Khajavi Gaskarei , Masoomeh Afzalipoor , Ali Mojtahedi , Neda Aligolighasemabadi , Ahmad Deilami , Samaneh Mirzaei Dahka , Mohammad-Hossein Keivanlou , Alireza Jafari","doi":"10.1016/j.ajur.2022.04.008","DOIUrl":"10.1016/j.ajur.2022.04.008","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to explore the global, prevalence, and risk factors of fever after percutaneous nephrolithotomy (PCNL) by conducting a systematic review and meta-analysis.</p></div><div><h3>Methods</h3><p>The high-sensitivity searching was conducted without time limitation until December 30, 2020 in Web of Sciences, Scopus, and PubMed based on inclusion and exclusion criteria.</p></div><div><h3>Results</h3><p>The prevalence rates of fever and sepsis among patient undergoing PCNL were estimated 9.5% (95% confidence interval [CI]: 9.3%–9.7%), and 4.5% (95% CI: 4.2%–4.8%), respectively. Nephrostomy tube was used in 9.96% (95% CI: 9.94%–9.97%) of patients. The mean preoperative white blood cells of patients were 6.401×10<sup>9</sup>/L; 18.3% and 4.55% of patients were considered as the positive urinary culture and pyuria, respectively. About 20.4% of patients suffered from residual stones. The odds ratios (ORs) of fever in patients who suffering from diabetes mellitus, hydronephrosis, staghorn stones, and blood transfusion were 4.62 (95% CI: 2.95–7.26), 1.04 (95% CI: 0.81–1.34), 2.57 (95% CI: 0.93–7.11), and 2.65 (95% CI: 1.62–4.35), respectively. Patients who underwent PCNL in prone position were more likely to develop fever (OR: 1.23; 95% CI: 0.75–2.00) than patients in supine position.</p></div><div><h3>Conclusion</h3><p>The current study showed that patients who suffer from diabetes mellitus, hydronephrosis, staghorn stones, nephrostomy tube or double-J stent, blood transfusion, and also patients who underwent PCNL in prone position surgery are more likely to develop a postoperative fever after PCNL.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 253-260"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000358/pdfft?md5=e538d4b6d756ddc3329d348d9daf35d3&pid=1-s2.0-S2214388223000358-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47127134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rheumatoid nephropathy is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA) associated with a very unfavorable prognosis. This study aimed to identify changes in renal function and morphological variations of kidney diseases in RA patients.
Methods
The study enrolled patients (126 patients) between 18 and 55 years of age with a confirmed active RA of more than 12 months. Each patient underwent the following range of laboratory and instrumental research methods: general clinical analysis of blood and urine, performing urinalysis according to Nechiporenko method; determining daily proteinuria; determining the blood content of glucose, urea, creatinine, uric acid, total bilirubin, liver transaminase level, ionogram, lipidogram, and coagulogram; determining the blood content of rheumatoid factor, anti-streptolysin O, and C-reactive protein; and X-ray of the joints of hands and feet. Renal function was examined by estimating glomerular filtration rate, tubular reabsorption index, and renal functional reserve. For studying the morphological changes in the kidneys under ultrasound examination, renal biopsy was performed in 31 patients with RA with urinary syndrome (proteinuria more than 0.3 g per day and hematuria).
Results
Nephropathy in RA is characterized by impaired renal function and manifested by an increased blood creatinine and a decrease in glomerular filtration rate and renal functional reserve. Among morphological variations of nephropathy at RA, mesangial proliferative glomerulonephritis prevails, accounting for 48.4% of patients. Other disorders include the secondary amyloidosis (29.0% of patients), tubulointerstitial nephritis (16.1%), membranous glomerulonephritis (3.2%), and focal-segmental glomerulosclerosis (3.2%).
Conclusion
Kidney damage is a common systemic manifestation of RA with a long and active course, a major nephropathy trigger.
目的类风湿肾病是类风湿性关节炎(RA)最严重的关节外表现之一,预后极差。本研究旨在确定 RA 患者肾功能的变化和肾脏疾病的形态学变化。研究方法:本研究招募了年龄在 18 岁至 55 岁之间、确诊活动性 RA 超过 12 个月的患者(126 名)。每位患者均接受了以下一系列实验室和仪器研究方法:血液和尿液的一般临床分析,根据 Nechiporenko 方法进行尿液分析;测定每日蛋白尿;测定血液中葡萄糖、尿素、肌酐、尿酸、总胆红素、肝脏转氨酶水平、离子图、血脂图和凝血图的含量;测定血液中类风湿因子、抗链球菌溶血素 O 和 C 反应蛋白的含量;以及手足关节的 X 光检查。通过估算肾小球滤过率、肾小管重吸收指数和肾功能储备来检查肾功能。为了研究超声检查下肾脏的形态学变化,对 31 名伴有泌尿系统综合征(蛋白尿超过每天 0.3 克且有血尿)的 RA 患者进行了肾活检。结果RA 肾病的特点是肾功能受损,表现为血肌酐升高、肾小球滤过率和肾功能储备下降。在 RA 肾病的形态变化中,系膜增生性肾小球肾炎占多数,占患者总数的 48.4%。其他疾病包括继发性淀粉样变性(29.0%的患者)、肾小管间质性肾炎(16.1%)、膜性肾小球肾炎(3.2%)和局灶性肾小球硬化(3.2%)。
{"title":"Changes in renal function and morphological variations of kidney diseases in rheumatoid arthritis patients","authors":"Yan Tang , Yuliya Varavko , Raisa Aringazina , Irina Menshikova","doi":"10.1016/j.ajur.2022.06.005","DOIUrl":"10.1016/j.ajur.2022.06.005","url":null,"abstract":"<div><h3>Objective</h3><p>Rheumatoid nephropathy is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA) associated with a very unfavorable prognosis. This study aimed to identify changes in renal function and morphological variations of kidney diseases in RA patients.</p></div><div><h3>Methods</h3><p>The study enrolled patients (126 patients) between 18 and 55 years of age with a confirmed active RA of more than 12 months. Each patient underwent the following range of laboratory and instrumental research methods: general clinical analysis of blood and urine, performing urinalysis according to Nechiporenko method; determining daily proteinuria; determining the blood content of glucose, urea, creatinine, uric acid, total bilirubin, liver transaminase level, ionogram, lipidogram, and coagulogram; determining the blood content of rheumatoid factor, anti-streptolysin O, and C-reactive protein; and X-ray of the joints of hands and feet. Renal function was examined by estimating glomerular filtration rate, tubular reabsorption index, and renal functional reserve. For studying the morphological changes in the kidneys under ultrasound examination, renal biopsy was performed in 31 patients with RA with urinary syndrome (proteinuria more than 0.3 g per day and hematuria).</p></div><div><h3>Results</h3><p>Nephropathy in RA is characterized by impaired renal function and manifested by an increased blood creatinine and a decrease in glomerular filtration rate and renal functional reserve. Among morphological variations of nephropathy at RA, mesangial proliferative glomerulonephritis prevails, accounting for 48.4% of patients. Other disorders include the secondary amyloidosis (29.0% of patients), tubulointerstitial nephritis (16.1%), membranous glomerulonephritis (3.2%), and focal-segmental glomerulosclerosis (3.2%).</p></div><div><h3>Conclusion</h3><p>Kidney damage is a common systemic manifestation of RA with a long and active course, a major nephropathy trigger.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 304-310"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388222001035/pdfft?md5=fd6acbec86b76f41611cd70f95a6577a&pid=1-s2.0-S2214388222001035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43600718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.ajur.2023.01.002
Stefano Salciccia , Marco Frisenda , Giulio Bevilacqua , Pietro Viscuso , Paolo Casale , Ettore De Berardinis , Giovanni Battista Di Pierro , Susanna Cattarino , Gloria Giorgino , Davide Rosati , Francesco Del Giudice , Alessandro Sciarra , Gianna Mariotti , Alessandro Gentilucci
Objective
To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases.
Methods
A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.
Results
Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: −0.03–0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16–0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78–1.88) and between high and low PLR was 1.47 (95% CI: 0.91–2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44–2.13) and between high and low PLR was 1.05 (95% CI: 0.87–1.24).
Conclusion
The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.
{"title":"Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review","authors":"Stefano Salciccia , Marco Frisenda , Giulio Bevilacqua , Pietro Viscuso , Paolo Casale , Ettore De Berardinis , Giovanni Battista Di Pierro , Susanna Cattarino , Gloria Giorgino , Davide Rosati , Francesco Del Giudice , Alessandro Sciarra , Gianna Mariotti , Alessandro Gentilucci","doi":"10.1016/j.ajur.2023.01.002","DOIUrl":"10.1016/j.ajur.2023.01.002","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases.</p></div><div><h3>Methods</h3><p>A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.</p></div><div><h3>Results</h3><p>Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: −0.03–0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16–0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78–1.88) and between high and low PLR was 1.47 (95% CI: 0.91–2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44–2.13) and between high and low PLR was 1.05 (95% CI: 0.87–1.24).</p></div><div><h3>Conclusion</h3><p>The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.</p></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 2","pages":"Pages 191-207"},"PeriodicalIF":2.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214388223000218/pdfft?md5=609e44a5457792c0763b5e54553ee3c2&pid=1-s2.0-S2214388223000218-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47029697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}